NasdaqCM:NAOV

Stock Analysis Report

Executive Summary

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has NanoVibronix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NAOV

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

-29.3%

NAOV

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: NAOV underperformed the US Medical Equipment industry which returned 10% over the past year.

Return vs Market: NAOV underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

NAOVIndustryMarket
7 Day0%3.2%3.4%
30 Day40.4%-1.8%-1.0%
90 Day-0.7%-0.4%-0.4%
1 Year-29.3%-29.3%10.9%10.0%7.7%5.4%
3 Year-45.6%-45.6%69.9%64.8%46.2%36.8%
5 Yearn/a128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is NanoVibronix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NanoVibronix undervalued compared to its fair value and its price relative to the market?

10.63x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate NAOV's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate NAOV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NAOV is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: NAOV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate NAOV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NAOV is overvalued based on its PB Ratio (10.6x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is NanoVibronix forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-2.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NAOV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NAOV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NAOV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NAOV's revenue (97.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: NAOV's revenue (97.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if NAOV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has NanoVibronix performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NAOV is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.

Accelerating Growth: Unable to compare NAOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NAOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: NAOV has a negative Return on Equity (-326.98%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NAOV is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NAOV is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is NanoVibronix's financial position?


Financial Position Analysis

Short Term Liabilities: NAOV's short term assets ($2.9M) exceeds its short term liabilities ($865.0K)

Long Term Liabilities: NAOV's short term assets (2.9M) exceeds its long term liabilities (307.0K)


Debt to Equity History and Analysis

Debt Level: NAOV is debt free.

Reducing Debt: NAOV currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: NAOV has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NAOV's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NAOV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NAOV has less than a year of cash runway if free cash flow continues to reduce at historical rates of -36% each year


Next Steps

Dividend

What is NanoVibronix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate NAOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NAOV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NAOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NAOV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NAOV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of NanoVibronix's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Brian Murphy (62yo)

3yrs

Tenure

US$590,897

Compensation

Mr. Brian M. Murphy has been the Chief Executive Officer of NanoVibronix Inc. since October 13, 2016. Mr. Murphy has over 25 years of sales, operations and general management experience in medical devices  ...


CEO Compensation Analysis

Compensation vs. Market: Brian's total compensation ($USD590.90K) is about average for companies of similar size in the US market ($USD493.02K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.0yrs

Average Tenure

63yo

Average Age

Experienced Management: NAOV's management team is considered experienced (3 years average tenure).


Board Age and Tenure

4.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: NAOV's board of directors are considered experienced (4.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Steve Brown (63yo)

    Consultant

    • Tenure: 0.4yrs
    • Compensation: US$225.47k
  • Jay Cardwell (58yo)

    Chief Financial Officer

    • Tenure: 0.4yrs
  • Harold Jacob (65yo)

    Chief Medical Officer & Director

    • Tenure: 16.1yrs
    • Compensation: US$10.59k
  • Amir Rippel

    Vice President of Marketing

    • Tenure: 0yrs
  • William Stern (77yo)

    President

    • Tenure: 3yrs
    • Compensation: US$231.60k
  • Brian Murphy (62yo)

    CEO & Director

    • Tenure: 3yrs
    • Compensation: US$590.90k
  • Lindsey Harrison

    Vice President of Sales

    • Tenure: 0yrs

Board Members

  • Shalom Hirschman (83yo)

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Tom Mika (66yo)

    Independent Director

    • Tenure: 4.5yrs
  • Chris Fashek (69yo)

    Independent Chairman of the Board

    • Tenure: 3yrs
    • Compensation: US$150.00k
  • Dennis Maki

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Harold Jacob (65yo)

    Chief Medical Officer & Director

    • Tenure: 16.1yrs
    • Compensation: US$10.59k
  • Phil Hanno

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Samuel Pinchas

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Yechezkiel Caine

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Mike Ferguson (47yo)

    Independent Director

    • Tenure: 4.5yrs
  • Brian Murphy (62yo)

    CEO & Director

    • Tenure: 3yrs
    • Compensation: US$590.90k

Company Information

NanoVibronix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NanoVibronix, Inc.
  • Ticker: NAOV
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$21.493m
  • Shares outstanding: 7.19m
  • Website: https://www.nanovibronix.com

Number of Employees


Location

  • NanoVibronix, Inc.
  • 525 Executive Boulevard
  • Elmsford
  • New York
  • 10523
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NAOVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015

Biography

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:14
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.